57 results about "Autoimmune Reactions" patented technology

The present invention relates to pharmaceutical compositions and methods for the prevention and treatment of autoimmune diseases, infectious diseases, neurodegenerative diseases, and primary and metastatic neoplastic diseases. In the practice of the invention, the compositions are employed comprising: (a) a heat shock protein (hsp) or an alpha(2)macroglobulin (alpha2M); (b) a saponin; and, optionally, (c) an antigenic molecule. The antigenic molecule displays the antigenicity of an antigen of: (a) a cell that elicits an autoimmune response; (b) an agent of an infectious disease; (c) a cancerous cell; or (d) a cell or structure associated with a neurodegenerative or amyloid disease. The hsps that can be used in the practice of the invention include but are not limited to hsp70, hsp90, gp96, calreticulin, hsp 110, grp 170, and PDI, alone or in combination with each other. The antigenic molecule can be covalently or noncovalently bound to the hsp or alpha2M, free in solution, and/or covalently bound to the saponin. The compositions of the invention can be administered alone or in combination with the administration of antigen presenting cells sensitized with an hsp- or alpha2M-antigenic molecule complex.

The OX-40 antigen is characterized and claimed together with variants and derivatives thereof. Also described are binding agents for the antigen and the use of these in diagnosis and therapy. Examples of such use include a method for the selective depletion of activated CD4+ T-cells in vivo by using immunotoxins comprising an OX-40 antibody conjugated to a toxic molecule (such as Ricin-A chain). The administration of these specific immunotoxins is used therapeutically to deplete autoimmune reactive CD4+ T-cells which have been implicated in diseases including Multiple Sclerosis, Rheumatoid Arthritis, Sarcoidosis, and Autoimmune Uveitis as well as inflammatory bowel disease and graft-versus-host disease. This type of therapy is also beneficial for eradicating CD4+ T-cell lymphomas and alloreactive CD4+ T-cells involved with a transplantation reaction. The use of the human form of the OX-40 antibody will also help in the early diagnosis of all the diseases mentioned above.

The invention relates to application of a series of indazole bi-aryl urea compounds and pharmaceutically acceptable salts thereof serving as protein kinase inhibitors to preparation of medicaments for treating diseases relevant to protein kinase activity, including tumors, inflammations, diseases relevant to autoimmunity reaction and diseases relevant to stem cells. As proved by experimental study, the indazole bi-aryl urea compounds and the pharmaceutically acceptable salts thereof play important roles in medical treatment and adjusting the activities of kinases such as KIT, PDGF (Platelet Derivation Growth Factor)-alpha, PDGF-beta, CSF1R (Colony Stimulating Factor 1 Receptor), DDR1and FLT3 of an original and/or mutative receptor tyrosine kinase (RTK) family and/or CDK8 (Cyclin-Dependent Kinase 8), CDK11 and HIPK4 (Homeodomain Interacting Protein Kinase 4) and the like of a CDK family. Preferred protein kinases are Kit, PDGF-alpha, PDGF-beta and FLT3 of the RTK family as well as CDK8 and CDK11 of the CDK family.

Type 1 diabetes mellitus is characterized by loss of pancreatic insulin-producing beta cells, resulting in insulin deficiency. The usual cause of this beta cell loss is autoimmune destruction. Coxsackie virus has been detected in human pancreatic beta cells and causes insulitis. This non-destructive islet inflammation does not itself cause diabetes, but this disease will occur if viral infection is followed by a separate autoimmune response. The insulitis is mediated mainly by natural killer cells. Islets from coxsackie virus positive samples displayed reduced insulin secretion in response to glucose and other secretagogues. Virus extracted from positive islets was able to infect beta cells from human islets of non-diabetic donors, causing viral inclusions and signs of pyknosis.

The invention discloses a kit for detecting an anti-GP73 antibody in serum, and belongs to the technical fields of medicines and biology. The kit comprises GP73 protein antigen, confining liquid, GP73 protein antigen of an enzyme label, a rabbit anti-human GP73 polyclonal antibody standard, a coating buffer, a developing solution, a scrubbing solution, a stop solution and a diluent, wherein the GP73 protein antigen has an amino acid sequence as shown in a sequence table SEQIDNO:1. According to the kit, the concentration of the anti-GP73 antibody in the serum of a patient can be accurately calculated, the existential level of the anti-GP73 antibody in the serum is really reflected, the kit can be applied to diagnosis of primary liver cancer in clinic, and the process of molecular change of the tumor can also be reflected by detecting the level of the anti-GP73 antibody, thereby judging the autoimmune response capacity of a silk body. The kit disclosed by the invention also has the advantages of good specificity, and high sensitivity, accuracy and precision.

The invention relates to a medicine for treating rheumatic heart disease, in particular to a traditional Chinese medicine composition for treating rheumatic heart disease which is made from plant Chinese herbal medicine. It is characterized in that, the raw material medicine that makes active ingredient is according to the following weight: Wujiapi 20-30 grams each, Radix Astragali 20-30 grams, Atractylodes macrocephala 20-30 grams, Poria cocos 15-25 grams, Radix Paeoniae Alba 15-25 grams , 5-15 grams of schisandra, 5-15 grams of licorice, 5-15 grams of salvia miltiorrhiza, 4-12 grams of cassia twig, 4-12 grams of sunburned aconite and 2-8 grams of asarum. All medicines of the present invention are compatible, complement each other, bring out the best in each other, have heat-clearing and toxic substances removing, expelling wind and relieving pain, regulating blood circulation and promoting blood circulation to remove blood stasis, eliminating stagnation and relieving pain etc., the synergistic action of drug effect can treat both symptoms and root causes, can reduce pathological integral, free radical, Reduce the autoimmune reaction of the heart, nourish the myocardium, improve blood supply and oxygen supply, and repair the lesion, thereby alleviating the pathological changes of the heart valve.

The invention concerns a first diagnostic method for glaucoma based on an analysis of autoimmune reactivity in body fluids against at least one sample of at least partially purified ocular antigens, wherein the autoimmune reactivity against individual antigens is measured and transformed into a glaucoma score to determine the diagnostic result. Further aspects of the invention include antigen carrying elements carrying at least one sample of the at least partially purified ocular antigens and kits for diagnosis of glaucoma. Further aspects include methods of collecting a body fluid such as tears for the use in the diagnostic method for glaucoma. Yet further aspects include ocular antigens serving as diagnostic markers and/or for preparing pharmaceutical compositions for treatment of glaucoma. The invention further concerns a second diagnostic method for glaucoma comprising the steps of a) providing an in vitro culture of cells; b) incubating a body fluid from a test individual with the in vitro culture of cells or incubating components, which are fractionated from the body fluid or from a body specimen of the test individual with the in vitro culture of cells; c) analyzing protein expression of the cells and/or analyzing the viability of the cells after treatment according to step b); and d) comparing the results of the analysis in step c) with standard data to determine a diagnostic result.

The invention discloses a mixed cell preparation and a preparation method and application thereof. The mixed cell preparation comprises mesenchymal stem cells, regulatory T cells and a solution; in the mixed cell preparation, the concentration of the mesenchymal stem cells is (1-10)*10<5>/ml, and the concentration of the regulatory T cells is (0.1-3)*10<6>/ml. The mixed cell preparation can promote regeneration and repair of pancreatic beta cells and inhibit damage of an autoimmunity reaction to the pancreatic beta cells, therefore, the mixed cell preparation can treat diabetes mellitus type 1, and pancreas islet transplantation is not needed.

Disclosed a modified and detoxified anticholinergic neurotoxic peptide that can suppress and prevent the onset of a T-cell mediated autoimmune reaction. The invention has application to the treatment of certain human autoimmune diseases, including especially multiple sclerosis, myasthenia gravis, and rheumatoid arthritis. More specifically, the method of treatment of autoimmune disorders is to administer a disease mitigating amount of a detoxified and neurotropically active modified alpha-neurotoxin composition.

The present invention relates to the area of improved anti-IgE antibodies and antigen binding agents, and compositions thereof, which target IgE, for instance: for use in treating disorders caused by IgE (such as allergic responses, or certain autoimmune responses); and, in particular, disorders caused by the interaction of IgE with the FcεRI receptor. In particular, this invention relates to improved anti-IgE antibodies and antigen binding agents related to novel mutants of omalizumab (Xolair®). The improved anti-IgE antibodies and antigen binding agents of the invention may have improved affinity for IgE and/or an improved interaction with the Cε2 domain of IgE and/or an improved modified epitope on IgE (for instance further involving the Cε2 domain of IgE) and/or the ability to disassociate IgE from the FcεRI receptor for instance at pharmaceutically-relevant concentrations. In one aspect, improved or novel treatments for IgE mediated disorders are disclosed in which IgE is targeted (for instance free IgE and/or IgE complexed with the FcεRI receptor).

The invention relates to a method for preparing an antiserum preparation, provides a method for preparing a swine multi-valent antiserum compound preparation, and aims to improve the prevention effect of swine multi-valent antiserum products. The method comprises the following steps of: sterilizing astragalus polysaccharide for 60 minutes at the temperature of 121 DGE C under the pressure of 100KPa; adding the sterilized astragalus polysaccharide solution into antiserum which contains antibodies of swine fever virus, porcine reproductive and respiratory syndrome virus and swine pseudorabies virus to form swine multi-valent antiserum compound solution and making the astragalus polysaccharide account for 1 mass percent of the compound solution; and irradiating the swine multi-valent antiserum compound solution by using 60Co-gamma rays to obtain the swine multi-valent antiserum compound preparation, wherein the irradiation temperature is between 15 and 25 DEG C; the irradiation dose rate is 5 to 20Gy/min; and the irradiation absorbed dose is 9 to 19kGy. The method has the advantages of protecting antibody activity, enhancing autoimmune reaction of organisms, achieving good emergent prevention and immune effect, along with simple and convenient operation and low cost.

A method of treatment of the human or non-human animal body for treating or preventing MMP-9-dependent disorders is disclosed, for example vascular syndromes, damages or diseases, atherosclerotic damages, arthritic conditions, inflammatory reactions, autoimmune reactions or proliferative diseases, which method comprises administering to a human or non-human animal body in need of such treatment an effective amount of a pharmaceutical composition containing dipyridamole, mopidamole or a pharmaceutically acceptable salt thereof, and the use of dipyridamole or mopidamole for the manufacture of a corresponding pharmaceutical composition.

The invention belong to Chinese traditional medicine field, relates to the application of eucommia polysaccharide for preparing medicine preventing systematic Cazenave's lupus. The invention separates polysaccharide extract from eucommia, the average productivity is 2.2%, and the polysaccharide content is more than 68%. It is showed by whole animal model test that the protective effect for hyper reaction and kidney injury for mice by said polysaccharide is distinctive, and it is proven that polysaccharide can prevent Cazenave's lupus syndrome. The eucommia polysaccharide can also be used to produce medicine preventing and treating self-immune disease.

The present invention discloses an application of BMP4 protein for preparation of drugs for autoimmune diseases. The BMP4 protein can be used as a protein preparation for regulating autoimmune responses after myocardial infarction after dredging blocked coronary artery, can reduce myocardial damage after the myocardial infarction, improves cardiac function after healing, and realizes myocardial regeneration and functional recovery after the myocardial infarction.

Various embodiments include methods for diagnosing and treating medical conditions that involve an autoimmune response to connective tissue such as collagen found in organs such as the lung. In one method pulmonary disease and disorders such as Idiopathic Pulmonary Fibrosis (IPF) are diagnosed by analyzing fluid or tissue samples obtained from a patient for evidence of an autoimmune response to various types of collagen including, for example, Type V. One type of assay for evidence of an autoimmune response to Type V collagen comprises the steps of obtaining a fluid or tissue sample from a patient, contacting at least a portion of the sample with antigen to anti-Type V collagen antibody and monitoring the mixture of sample and antigen for changes indicative of the presence of anti-Type V collagen in the sample. Another embodiment includes treating pulmonary diseases such as IPF by administering a therapeutically effective dose of epitopes of various collagens including Type V collagen.

The invention relates to a liver protecting and calming pill which has the efficacy of clearing heat and promoting diuresis, benefiting liver and removing blood stasis, soothing liver and relieving pain, removing jaundice and lowering glutamic-pyruvic transaminase, and is suitable for treating acute hepatitis and chromic hepatitis and the active components of which consists of the medicinal materials of stringy stonecrop, giant knotweed, red sage root and ganoderma lucidum, and a preparation method thereof. The liver protecting and calming pill prompts an organism to play the normal immunologic role, start a liver self-healing system, block autoimmune reaction and strength physique and anti-virus ability; recovers the normal detoxification function of the liver to cause normal operation of human body; resists liver damage to effectively inhibit the increase of serum glutamic-pyruvic transaminase (SGPT), serum glutamic-oxaloacetic transaminase (SGOT) and lactate dehydrogenase (LDH); and increases hemoglobin to obviously increase the Hb content of blood plasma. The liver protecting and calming pill keeps stable blood-drug level and fully play the drug effect according to the theory of long-term administration for liver disease and the 'sluggish characteristic of pills' .

Autoimmune reactions to certain epitopes of self antigens most likely contribute to the development of rheumatoid arthritis. Often these epitopes are citrullinated. The present invention relates generally to novel antibodies that can bind to certain citrullinated epitopes namely citrullinated enolase, vimentin, fibrinogen and citrullinated synthetic peptides. These antibodies can be used in diagnostics of rheumatoid arthritis, for therapy against rheumatoid arthritis and as research tools.

The invention belong to Chinese traditional medicine field, relates to the application of bupleurum root polysaccharide for preparing medicine preventing systematic Cazenave's lupus. The invention separates polysaccharide extract from bupleurum root, the average productivity is 3.32%, and the polysaccharide content is more than 65%. It is showed by whole animal model test that the protective effect for hyper reaction and kidney injury for mice by said polysaccharide is distinctive, and it is proven that polysaccharide can prevent Cazenave's lupus syndrome. The bupleurum root polysaccharide can also be used to produce medicine preventing and treating self-immune disease.

The invention provides a method for preparing TCR knockout T cell receptor gene-modified T cells targeting TIPE3, which comprises the following steps: by knocking out the TCR gene on T lymphocytes andpreparing T cell receptors targeting TIPE3, and the TCR knockout T cell receptor gene-modified T cell targeting TIPE3 is obtained. The TCR knockout T cell receptor gene-modified T cell targeting TIPE3 can effectively prevent the mismatch of endogenous and exogenous TCR alpha-chain and beta-chain existing in T cells, autoimmune responses are avoided, and efficient and specific killing performanceof TIPE3 positive tumor cells can be kept. The method also provides an application of TCR knockout T cell receptor gene-modified T cells targeting TIPE3.